Nasdaq:ARVN
ARVINAS, INC.
A rare disease-focused biopharmaceutical developer leveraging a proprietary small molecule pipeline to address unmet oncology and neurological needs.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to the significant cash position of $142.9M and recent positive cash flow from investing activities of $407.6M, suggesting strong balance sheet liquidity. The substantial revenue rebound in 2024 and 2025 combined with a manageable debt load could signal a turning point toward profitability if clinical milestones are met.
Bear Case
The company faces severe financial pressure with an accumulated retained earnings deficit of -$1.61B and negative net profit for five consecutive years. Heavy investment in R&D ($285.2M) and general administrative costs ($95.9M) alongside a massive cash burn from operations (-$273.8M) raises concerns about capital sustainability without new funding.
About ARVINAS, INC.
Arvinas Inc. is a biopharmaceutical company specializing in developing small molecule drugs for rare diseases, with a primary focus on oncology and neurological disorders. The company serves markets in the United States and Europe through its proprietary pipeline of novel therapeutic agents. Revenue growth in 2024 and 2025 reflects accelerated commercialization or strategic asset acquisitions within this specialized niche.
Analysis
Management Discussion
The company reported revenue of $262.6M in 2025, marking a near-doubling from the previous year and indicating successful commercial scaling or deal activity. Despite this revenue milestone, net income remains negative at -$80.8M, driven by substantial R&D expenditures of $285.2M and operating expenses of $381.1M, which is typical for a growth-stage biotech firm.
Industry Overview
The biopharmaceutical industry for rare diseases is characterized by high failure rates, substantial regulatory hurdles, and the need for specialized manufacturing capabilities. Success in this sector often relies on innovative mechanisms of action that differentiate products from generic therapies or established competitors.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $131.4M | $78.5M | $263.4M | $262.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $131.4M | $78.5M | $263.4M | $262.6M |
| Operating Expenses | $394.6M | $480.0M | $513.6M | $381.1M |
| Operating Income | $-263.2M | $-401.5M | $-250.2M | $-118.5M |
| R&D | $315.0M | $379.7M | $348.2M | $285.2M |
| G&A | $79.6M | $100.3M | $165.4M | $95.9M |
| Stock-Based Comp | $75.5M | $71.6M | $88.2M | $44.0M |
| D&A | $6.3M | $4.8M | $4.6M | $3.0M |
| Depreciation | $6.3M | $4.8M | $4.6M | — |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $12.2M | $37.6M | $51.9M | $38.0M |
| Interest Expense | — | $0 | $0 | — |
| Interest Income | $12.0M | $38.8M | $54.8M | $38.4M |
| Pre-Tax Income | $-251.0M | $-363.9M | $-198.3M | $-80.5M |
| Income Tax | $20.9M | $900.0K | $600.0K | $300.0K |
| Continuing Ops | $-271.9M | $-364.8M | $-198.9M | $-80.8M |
| Discontinued Ops | $-10.6M | $-2.5M | $0 | $0 |
| Net Income | $-282.5M | $-367.3M | $-198.9M | $-80.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-282.5M | $-367.3M | $-198.9M | $-80.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.24B | $1.28B | $1.07B | $700.7M |
| Cash & Equivalents | $81.3M | $311.7M | $100.5M | $142.9M |
| Marketable Securities | $1.12B | $949.3M | $938.9M | $542.5M |
| Accounts Receivable | $1.0M | $0 | $5.7M | $1.0M |
| Prepaid Expenses | $21.4M | $6.5M | $14.2M | $8.9M |
| Other Current Assets | $12.5M | $12.7M | $8.0M | $5.4M |
| Long-Term Assets | $28.6M | $24.4M | $24.1M | $17.2M |
| PP&E (Net) | $13.4M | $11.5M | $7.0M | $5.2M |
| Operating Leases | $4.4M | $2.5M | $9.0M | $8.2M |
| Other LT Assets | $10.8M | $10.4M | $8.1M | $3.8M |
| Total Assets | $1.27B | $1.30B | $1.09B | $717.9M |
| Current Liabilities | $295.1M | $257.1M | $229.8M | $142.5M |
| Accounts Payable | $5.7M | $17.8M | $13.4M | $24.4M |
| Current Debt | — | $200.0K | $200.0K | $200.0K |
| Current Leases | $1.8M | $1.9M | $1.8M | $1.7M |
| Deferred Revenue | $218.6M | $163.0M | $156.2M | $71.3M |
| Taxes Payable | $10.3M | $700.0K | $3.2M | $4.8M |
| Other Current Liab | $58.7M | $73.5M | $55.0M | $40.1M |
| Long-Term Liabilities | $408.8M | $387.5M | $299.9M | $141.5M |
| Long-Term Debt | $1.0M | $800.0K | $600.0K | $400.0K |
| LT Operating Leases | $2.7M | $500.0K | $7.3M | $6.8M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $703.9M | $644.6M | $529.7M | $284.0M |
| Shareholders' Equity | $564.9M | $660.0M | $561.7M | $433.9M |
| Paid-In Capital | $1.55B | $2.00B | $2.09B | $2.14B |
| Retained Earnings | $-965.4M | $-1.33B | $-1.53B | $-1.61B |
| AOCI | $-19.2M | $-3.1M | $1.0M | $1.2M |
| Total L&E | $1.27B | $1.30B | $1.09B | $717.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-282.5M | $-367.3M | $-198.9M | $-80.8M |
| Non-Cash Adjustments | $121.5M | $93.7M | $47.2M | $65.9M |
| Working Capital Changes | $-112.5M | $-74.2M | $-107.6M | $-258.9M |
| Cash from Operations | $-273.5M | $-347.8M | $-259.3M | $-273.8M |
| Capital Expenditures | $6.8M | $2.9M | $1.8M | $1.9M |
| Cash from Investing | $242.8M | $203.5M | $34.7M | $407.6M |
| Debt Repayments | — | — | $400.0K | $200.0K |
| Share Buybacks | — | — | — | $91.9M |
| Cash from Financing | $4.7M | $374.7M | $7.9M | $-91.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-26.0M | $230.4M | $-216.7M | $42.4M |
| Beginning Cash | $112.8M | $86.8M | $317.2M | $100.5M |
| Ending Cash | $86.8M | $317.2M | $100.5M | $142.9M |
Frequently Asked Questions
How does ARVINAS, INC. make money?
Oncology Therapeutics, Neurological Disorder Treatments, Rare Disease Programs, Commercial Licensing Partnerships
What are the main risks for ARVN?
High dependence on a limited number of product candidates, potential for clinical trial failures or regulatory delays, significant cash burn requiring future financing, intense competition from larger biopharma entities.
What is ARVN's competitive advantage?
Proprietary small molecule drug discovery platform, specialized expertise in rare disease mechanisms, strategic partnerships that offset R&D capital intensity.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.